In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer

被引:44
作者
Fodero-Tavoletti, Michelle T. [1 ,2 ]
Brockschnieder, Damian [3 ]
Villemagne, Victor L. [4 ,5 ,6 ]
Martin, Lucas [3 ]
Connor, Andrea R. [1 ,2 ]
Thiele, Andrea [3 ]
Berndt, Mathias [3 ]
McLean, Catriona A. [7 ]
Krause, Sabine [3 ]
Rowe, Christopher C. [4 ,5 ]
Masters, Colin L. [6 ]
Dinkelborg, Ludger [3 ]
Dyrks, Thomas [3 ]
Cappai, Roberto [1 ,2 ]
机构
[1] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia
[2] Univ Melbourne, Mol & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia
[3] Global Drug Discovery, Bayer HealthCare Pharmaceut, Berlin, Germany
[4] Austin Hlth, Dept Nucl Med, Melbourne, Vic 3084, Australia
[5] Austin Hlth, Ctr PET, Melbourne, Vic 3084, Australia
[6] Mental Hlth Res Inst, Parkville, Vic 3052, Australia
[7] Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3181, Australia
基金
英国医学研究理事会;
关键词
A beta; Imaging; Alzheimer's disease; Dementia; PET; PRECLINICAL ALZHEIMERS-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; AMYLOID-BETA; LEWY BODIES; PET; DEMENTIA; PLAQUES; BRAIN; CONSORTIUM;
D O I
10.1016/j.nucmedbio.2012.03.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Amyloid-beta (A beta) plagues are a major pathological hallmark of Alzheimer's disease (AD). The noninvasive detection of A beta plagues may increase the accuracy of clinical diagnosis as well as monitor therapeutic interventions. While [C-11]-PiB is the most widely used A beta positron emission tomography (PET) radiotracer, due to the short half-life of C-11 (20 min), its application is limited to centers with an on-site cyclotron and C-11 radiochemistry expertise. Therefore, novel [F-18] (half-life 110 min)-labeled A beta PET tracers have been developed. We have demonstrated that [F-18]-florbetaben-PET can differentiate individuals diagnosed with AD from healthy elderly, Parkinson's disease and frontotemporal lobe dementia (FTLD-tau) patients. While [F-18]-florbetaben-PET retention matched the reported postmortem distribution of A beta plagues, the nature of [F-18]-florbetaben binding to other pathological lesions comprising misfolded proteins needs further assessment. The objective of this study was to determine whether Florbetaben selectively binds to A beta plagues in postmortem tissue specimens containing mixed pathological hallmarks (i.e., tau and alpha-synuclein aggregates). Method: Human AD, FTLD-tau and dementia with Lewy bodies (DLB) brain sections were analyzed by [F-18]-florbetaben autoradiography and [H-3]-florbetaben high-resolution emulsion autoradiography and [F-19]-florbetaben fluorescence microscopy. Results: Both autoradiographical analyses demonstrated that Florbetaben exclusively bound A beta plagues in AD brain sections at low nanomolar concentrations. Furthermore, at concentrations thousand-folds higher than those during a PET scan, [F-19]-florbetaben did not bind to alpha-synuclein or tau aggregates in DLB and FTLD-tau brain sections, respectively. Detection of [F-19]-florbetaben staining by fluorescence microscopy in several AD brain regions demonstrated that Florbetaben identified A beta plaques in all brain regions examined. Conclusion: This study provides further evidence that [F-18]-florbetaben-PET is a highly selective radiotracer to assess A beta plague deposition in the brain. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:1042 / 1048
页数:7
相关论文
共 35 条
[11]  
LeVine H, 1999, METHOD ENZYMOL, V309, P274
[12]   Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography [J].
Maeda, Jun ;
Ji, Bin ;
Irie, Toshiaki ;
Tomiyama, Takami ;
Maruyama, Masahiro ;
Okauchi, Takashi ;
Staufenbiel, Matthias ;
Iwata, Nobuhisa ;
Ono, Maiko ;
Saido, Takaomi C. ;
Suzuki, Kazutoshi ;
Mori, Hiroshi ;
Higuchi, Makoto ;
Suhara, Tetsuya .
JOURNAL OF NEUROSCIENCE, 2007, 27 (41) :10957-10968
[13]   Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics [J].
Masters, Colin L. ;
Cappai, Roberto ;
Barnham, Kevin J. ;
Villemagne, Victor L. .
JOURNAL OF NEUROCHEMISTRY, 2006, 97 (06) :1700-1725
[14]   Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop [J].
McKeith, IG ;
Galasko, D ;
Kosaka, K ;
Perry, EK ;
Dickson, DW ;
Hansen, LA ;
Salmon, DP ;
Lowe, J ;
MIrra, SS ;
Byrne, EJ ;
Lennox, G ;
Quinn, NP ;
Edwardson, JA ;
Ince, PG ;
Bergeron, C ;
Burns, A ;
Miller, BL ;
Lovestone, S ;
Collerton, D ;
Jansen, ENH ;
Ballard, C ;
deVos, RAI ;
Wilcock, GK ;
Jellinger, KA ;
Perry, RH .
NEUROLOGY, 1996, 47 (05) :1113-1124
[15]  
Morris JC, 2009, ARCH NEUROL-CHICAGO, V66, P1469, DOI 10.1001/archneurol.2009.269
[16]   PET imaging of amyloid in Alzheimer's disease [J].
Nordberg, A .
LANCET NEUROLOGY, 2004, 3 (09) :519-527
[17]   Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial [J].
Patt, M. ;
Schildan, A. ;
Barthel, H. ;
Becker, G. ;
Schultze-Mosgau, M. H. ;
Rohde, B. ;
Reininger, C. ;
Sabri, O. .
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2010, 284 (03) :557-562
[18]  
Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO
[19]  
2-X
[20]   11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study [J].
Rinne, Juha O. ;
Brooks, David J. ;
Rossor, Martin N. ;
Fox, Nick C. ;
Bullock, Roger ;
Klunk, William E. ;
Mathis, Chester A. ;
Blennow, Kaj ;
Barakos, Jerome ;
Okello, Aren A. ;
de Llano, Sofia Rodriguez Martinez ;
Liu, Enchi ;
Koller, Martin ;
Gregg, Keith M. ;
Schenk, Dale ;
Black, Ronald ;
Grundman, Michael .
LANCET NEUROLOGY, 2010, 9 (04) :363-372